Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04880863
Title Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC (NT-NAP-102-1)
Acronym NT-NAP-102-1
Recruitment Completed
Gender
Phase Phase II
Variant Requirements No
Sponsors NeoTX Therapeutics Ltd.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
NeoTX - 10307 Daphne Alabama 36526 United States Details
NeoTX - 10302 Scottsdale Arizona 85258 United States Details
NeoTX - 10303 Tucson Arizona 85711 United States Details
NeoTX - 10306 Lone Tree Colorado 80124 United States Details
NeoTX - 10304 Minneapolis Minnesota 55404 United States Details
NeoTX - 10100 Morristown New Jersey 07962 United States Details
NeoTX - 10308 Austin Texas 78745 United States Details
NeoTX - 10309 Dallas Texas 75246 United States Details
NeoTX - 10312 El Paso Texas 79902 United States Details
NeoTX - 10310 Tyler Texas 75702 United States Details
NeoTX - 10311 Fairfax Virginia 22205 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field